News | May 02, 2026
FDA renews IQOS “reduced-risk” status backing PMI’s smoke-free strategy in regulatory win
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
The Danish biotech company confirmed the global study will begin in the second half of 2026
After Phase 3 results show major hair regrowth gains
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
The submission is backed by positive results from the Phase 3 AFFIRM study
The approval was driven by data from the Phase III TULIP-SC trial
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Subscribe To Our Newsletter & Stay Updated
